MEDP Price Prediction Next Week
Technical Analysis: Based on recent price action, MEDP has shown significant weakness after its Q4 earnings report. The stock dropped 6.9% following earnings and continued to decline, currently trading at $327.32.
Key technical indicators suggest:
- Stock is in a horizontal trend with support at $326.11
- Volume declined on recent gains, indicating potential weakness
- Current trading range expected between $324.95 and $359.39 with 90% probability
Fundamental Analysis: Q4 2024 Results:
- Revenue: $536.6M (beat estimates by $1.82M)
- EPS: $3.67 (beat estimates by $0.71)
- New business awards: $529.7M (-13.8% YoY)
- Backlog: $2.9B (+3.2% YoY)
2025 Outlook:
- Revenue guidance: $2.11B-$2.21B
- EPS guidance: $11.93-$12.69
Price Prediction for Next Week: Based on technical and fundamental factors:
- Support level: $326.11
- Resistance level: $337.61
- Expected trading range: $324.95-$337.61
The stock is likely to remain under pressure in the short term due to:
- Declining volume on price increases
- Negative signals from moving averages
- Weaker new business awards growth
Recommendation: SELL
- Current price ($327.32) is near support level
- Technical indicators suggest continued weakness
- Set stop-loss at $330.21 (recent high)
- Target price: $324.95 (lower support)
Note: The stock market is currently closed (Monday pre-market). Trading recommendations should be executed when market opens.
MEDP Similar Chart Price Prediction
The price of MEDP is predicted to go up -0.89%, based on the high correlation periods with LAMR. The similarity of these two price pattern on the periods is 94.28%.
MEDP
LAMR
Down: -0.89%Similarity: 94.28%
MEDP Revenue Forecast
MEDP EPS Forecast
MEDP FAQs
What is MEDP revenue forecast for next quarter？
MEDP VS S&P500
Medpace's small and midsize biopharma customers are very dependent on outsourced clinical trials since they do not have the capacity to run trials in-house.
Medpace's operational discipline should support strong earnings growth and high returns as the company continues to expand.
Medpace is poised to benefit from steadily increasing levels of outsourced clinical trials and complex novel therapeutics, such as biologics and gene therapies.
MEDP Analyst's Forecast
Eric Coldwell
Baird
Hold
2024-11-25
Price Target
$349 → $354
Upside
+4.79%
Baird raised the firm's price target on Medpace to $354 from $349 and keeps a Neutral rating on the shares. The firm said the sector chop, political headlines galore, and presently weak biotech funding each keep them more guarded than normal. Yet this is exactly the type of company that long-term investors should crave and the firm has a very positive long-term bias on the shares.
Charles Rhyee
TD Cowen
Strong Buy
2024-10-23
Price Target
$413 → $372
Upside
+12.7%
Eric Coldwell
Baird
Buy → Hold
2024-10-23
Price Target
$413 → $349
Upside
+5.74%
